Emerging drugs for bipolar disorder
- 6 May 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Emerging Drugs
- Vol. 15 (3) , 453-466
Abstract
(2010). Emerging drugs for bipolar disorder. Expert Opinion on Emerging Drugs: Vol. 15, No. 3, pp. 453-466.Keywords
This publication has 91 references indexed in Scilit:
- Validating GSK3 as an in vivo target of lithium actionBiochemical Society Transactions, 2009
- The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesisBipolar Disorders, 2009
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaTrends in Pharmacological Sciences, 2009
- Early intervention in bipolar disorder, part II: therapeuticsEarly Intervention in Psychiatry, 2008
- Bipolar disorder: candidate drug targetsMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2008
- A 12‐week open‐label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late‐life bipolar disorderInternational Journal of Geriatric Psychiatry, 2008
- NeuroprotectionArchives of Neurology, 2007
- Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2007
- Antidepressant Efficacy of the Antimuscarinic Drug ScopolamineArchives of General Psychiatry, 2006
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005